CPhI Japan 2018 | 18-20 April 2018 Big Sight Exhibition Center, Tokyo

How to apply for Seminars

Keynote Seminar / Special Seminar

Keynote Seminars

Venue: Keynote/Special Seminar Room K, East Hall 3
Capacity: 600 Seats
18 April, 2018
K-1
9:15
|
10:30
Current topics regarding regulation of pharmaceuticals in Japan
Mrs. Fumi Yamamoto,
Director, Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau,
Ministry of Health, Labour and Welfare (MHLW)

※The opening ceremony will be held at the beggining of the seminar.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


19 April, 2018
K-6
9:30
|
10:45
Pricing system reform in 2018 and introduction of cost-effectiveness assessment
Dr. Makoto Shiragami,
Professor, Department of Pharmaceutical Sciences,
Teikyo Heisei University

【Language: English/Japanese】

Drastic reform of NHI drug price system was carried out recently from the viewpoint of achieving both "sustainability of national public insurance" and "promotion of innovation". In addition, a cost-effectiveness assessment was introduced, and as a first step, price adjustments were made for the items subject to trial implementation. I will explain these outlines and forecast future developments.


20 April, 2018
K-11
9:30
|
11:00
Coming soon!
1. Target of PMDA International Strategic Plan 2015 and the Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs

Dr. Junko Sato,
Office Director, Office of International Cooperation,
Pharmaceuticals and Medical Devices Agency

PMDA established the Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs in April 2016 to share its experiences and knowledges based on PMDA Strategic Plan 2015. In this presentation, I would like to show targeted outcome of the Center.

2. Business Operation & Strategy of R&D based Pharmaceutical Companies of Japan

Mr. Tomoyuki Otsuka,
Executive Member, International Affairs,
Vice Chair, Asia Committee, International Affairs,
UK WG Leader, Europe-US Committee, International Affairs, International Affairs,
Japan Pharmaceutical Manufacturers Association
Head, Public Affairs International,
Takeda Pharmaceutical Company, Limited
--------------------------------------------------------
Japan Pharmaceutical Manufacturers Association (JPMA) consists of R&D based Pharmaceutical companies of Japan. JPMA set up Industrial Vision 2025 last year and advocates "Providing innovative drugs to 8 billion people worldwide" JPMA members position Asia as a strategically important market. However healthcare infrastructure of Asian market is still underdeveloped and needs a lot of improvements. JPMA has been collaborating with Japanese government in various activities in order to help the countries improve people's access to innovative medicines.

3. Improving access to innovative medicines for Asian countries from the viewpoint of product quality and GMP

Dr. Yasuyuki Ikematsu,
Chairperson, GMP Expert Committee, Quality and Technology Committee,
 Japan Pharmaceutical Manufacturers Association
Director, Japan Regional Quality, Global Quality HQs,
Eisai Co., Ltd.
-------------------------------------------------------
JPMA has been working on promotion of the convergence of GMP investigation/review and post-approval variations with Asian countries to expedite the launch of innovative medicines for the peoples in Asia.  Additionally, for Asia Training Center which PMDA promotes, GMP Expert Committee has been providing actual manufacturing facilities as on-site mock inspection to build regulatory capacity for regulators in Asia.  In this presentation, I introduce the results and prospects of these activities.

【Panel Discussion】
I facilitate the panel discussions with regard to pharmaceutical development and business activities with Asian countries in addition to the position of Japan at Asia through 3 (three) presenters.

Moderator
Mr. Kenji Kamiya,
Chairperson, Quality Committee,
Japan Pharmaceutical Manufacturers Association
Officer, Quality Headquarters, Japan Regional Quality,
Eisai Co., Ltd.
 
Dr. Junko Sato
Mr. Tomoyuki Otsuka
Dr. Yasuyuki Ikematsu
Mr. Kenji Kamiya


Special Seminars

Venue: Keynote/Special Seminar Room K, East Hall 3
Capacity: 600 Seats
18 April, 2018
K-2
11:00
|
12:00
A New roadmap of Generic Medicine
- Aiming for 80% era -
Dr. Masaki Muto M.D.,  Ph.D.
Professor,
Health Policy and Management,
International University of Health and Welfare Graduate School
Chairman, 
Japanese Society of Generic and Biosimilar Medicines

In June 2017, the government set the target market share of generic drugs to 80% by September 2020, and examined a new generic drug roadmap for promoting the spread of generic drugs towards the goal.  In the lecture, we describe the present issues of generic drugs and future strategies toward 80% goal. We will also describe current issues and future strategies for out of patent biologic drug, biosimilars.


K-3
13:00
|
14:00
Present status and future of AI
-based Drug Discovery
Prof. Hiroshi Tanaka,
Professor Emeritus, Specially appointed professor,
division of medical data science promotion, Tokyo Medical and Dental University
Special Advisor to Executive Director, Specially appointed professor,
Tomoku Medical Megabank Organization, Tohoku University

Recently, interests in application of artificial intelligence to drug discovery is highly increasing. In this lecture, I will classify the computational drug discovery and DR (drug repositioning) into “non-learning” and “learning” approaches and review the international situation of the research activities on “AI-based drug discovery”, with special emphasis on the application of “deep learning” to it.


K-4
15:00
|
16:00
AI-powered Drug Discovery Research
Ph.D Tadashi Kadowaki,
Senior Director, Data Science Laboratory,
hhc Data Creation Center,
Eisai Co., Ltd. 

Data Science Laboratory in Eisai has been established since Apr. 2016. 
Two-year activity of AI-powered drug discovery research will be presented. 


19 April, 2018
K-7
11:15
|
12:15
AMED activities for innovative drug discovery in Japan
Mr. Noriatsu Kono,
Managing Director,
Department of Innovative Drug Discovery and Development,
Japan Agency for Medical Research and Development (AMED)

【Language: English/Japanese】

AMED was established in April 2015, consideration with providing a single window of support and funding for medical research and development (R&D) in line with government policy.  In this session I will try to introduce AMED challenges for innovative drug discovery and the R&D circumstance in Japan.


K-8
13:30
|
15:10
【Part 1】
CPhI Japan 2018
 International API Procurement Forum
“Secure Supply and Quality Control of APIs to meet requirements of the age of generic market share of 80%”
​Organizer: Japan Pharmaceutical Traders’ Association   
【Language: English/Japanese (Simultaneous Translation)】

Session 1 ― Proposal of joint audit
                                                                                                           
1. Opening Statement of Head of Organizer
Mr. Hideo Tsunoda, Chairman, Japan Pharmaceutical Traders’ Association)

2. Current situation of the GMP Investigation by PMDA and the future outlook of GMP
Ryoko Naruse, Ph.D.
Division Director Office of Manufacturing
Quality and Compliance Division of Pharmaceuticals,
Pharmaceuticals and Medical Devices Agency

3. Introduction that NPO-QA Center implements the third party GMP verification of common API from foreign manufacturing plant
Mr. Hirotaroh Yorozu,
NPO Drug and Food Quality Assurance Support Center

4. Panel Discussion

Japan Pharmaceutical Traders’ Association, Pharmaceuticals and Medical Devices Agency, NPO Drug and Food Quality Assurance Support Center
Ryoko Naruse, Ph.D.
Mr. Hirotaroh Yorozu


K-9
16:00
|
17:00
【Part 2】
CPhI Japan 2018
 International API Procurement Forum
“Secure Supply and Quality Control of APIs to meet requirements of the age of generic market share of 80%” 
Organizer: Japan Pharmaceutical Traders’ Association  
【Language: English/Japanese(Simultaneous Translation)】

Session 2 -  Change control  

1. API manufacturer’s experience with a global change:  a case study
APIC-CEFIC, EU Global Regulatory Specialist, Aspen Oss B.V. Ms. Marieke Van Dalen     

2. Experience and Inspection of Change Control
Pharmaceuticals and Medical Devices Agency, Office of Generic Drugs Reviewer
Kana Watanabe, Ph.D.

3. Losing Remarks
Mr. Ichiro Fujikawa,
Vice Chairman,
Japan Pharmaceutical Trader's Association
Ms. Marieke Van Dalen
​Kana Watanabe, Ph.D.


20 April, 2018
K-12
11:30
|
12:00
The Act on the Next-Generation Medical Infrastructure
Mr. Kanau Yamada,
Director, Office of Healthcare Policy,
Cabinet Secretariat, Government of Japan

Introduce the overview of “The Act on the Next-Generation Medical Infrastructure” promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.


K-13
13:00
|
14:00
How we should address data integrity?
Mr. Masayuki Akutagawa,
Director Division Manager, Business Development Division,
Pharma planning Co., Ltd.

Mr. Hiroomi Nishimura,
Manager, Research & Development Department
Analytical & Measuring Instruments Division,
Shimadzu Corporation

Mr. Tsutomu Kojima
Pharma planning Co., Ltd.
Former: Ono Pharmaceutical Co., Ltd.
Over a year after the FDA and PIC/S have issued guidelines about data integrity. Various efforts continue in the field. Blind responses result in a large increase in load. We would like to exchange opinions from the standpoint of the regulated organizations and a supplier on how to deal with the situation in the field, and share tips on how to deal with the situation with the venue.
Mr. Masayuki Akutagawa
Mr. Hiroomi Nishimura
Mr. Tsutomu Kojima


K-14
14:30
|
15:30
For the extension of healthy life-span:
JMA’s expectations to the pharmaceutical industry
MD, PhD. Yutaka Hatori,
Executive board member,
Japan Medical Association

The Japan Medical Association supports various approaches for increasing healthy life expectancy, and as a promoting innovation, accelerates developments of new medical devices proposed by physicians and physician-initiated clinical trials. The clinical study law will improve transparency of the relationship between physicians conducting clinical studies and industrial companies. In order to promote the use of generic drugs, it requires to enhance quality, supply and information in the post-marketing.


K-15
16:00
|
16:50
We are standing at the historical turning point of medical products regulation
Mr. Shigeki Tsuda,
Senior Managing Director,
Pharmaceutical and Medical Device Regulatory Science Society of Japan (PMRJ)



Conference

Venue: Conference Room F, East Hall 3
Capacity: 200 Seats
18 April, 2018
F-1
10:30
|
11:30
The Reason why Japan made API is selected
Mr. Ryotaro Katsura,
Katsura Chemical Co.,Ltd.

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


F-2
12:00
|
13:00
CPhI Women 2018
Part 1: Work style reform for women
Ms. Mariko Mimura,
Vice President, General Counsel, Compliance Officer and Head of External Affairs, Attorney at Law/Patent Attorney,
GlaxoSmithKline K.K.

Ms. Kuniko Shoji,
Corporate Advisor,
TERUMO CORPORATION

Kumi Arakane, Ph.D.
Audit & Supervisory Board Member (KANSA-YAKU),
KOSÉ Corporation

Ms.  Asako Aoyama,
Executive Officer, Transformation Project Leader
Coca-Cola Bottlers Japan Inc.
 
Ms. Mariko Mimura
Ms. Kuniko Shoji
Kumi Arakane, Ph.D.
Ms. Asako Aoyama


F-3
13:15
|
14:15
Aim for the world's first non-standard peptide CMO !
Mr. Kiichi Kubota,
President & CEO,
PeptiStar Inc.

At the moment, more than 60 pipelines are underway worldwide for drug discovery development with non-standard peptides. However, the supply system of drug substance in GMP, which is required in the future, has not been prepared.
I will introduce the present state and future vision of PeptiStar Inc. established as a non-standard peptide CMO that can respond to future demand.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


F-4
14:35
|
15:35
Continuous Manufacturing for Solid Dosage Formulation and Continuous Manufacturing Project Activities in Pharmaceutical Expert Committee, the Japan Pharmaceutical Manufacturers Association
Mr. Tomoaki Ohta,
Continuous Manufacturing Project Leader,
Pharmaceutical Expert Committee, Quality & Technology Committee,
Japan Pharmaceutical Manufacturers Association (JPMA)
Formulation Technology 3 Group Manager,
Production Engineering Dept. (Formulation Technology), Pharmaceutical Technology Div.,
Chugai Pharmaceutical Co., Ltd.

Continuous manufacturing technology is greatly expected to have the potential to reduce the development cost and time and to improve the productivity and product quality. The technology development is ongoing in some domestic pharmaceutical companies. I would like to introduce the features of the continuous manufacturing technology for solid dosage formulation and the current situation of industry activities in Japan. In addition, I will comment the document “Points to Consider Regarding Continuous Manufacturing” which was summarized in 2017.


F-5
15:50
|
16:50
Contract manufacturing in Japan will be restored with continuous manufacturing
Dr. Takao Saito,
President, Takasago Chemical Corporation
Fellow, Takasago International Corporation

Production cost reduction in the fierce competition occurs globally.  In Japan, the existing production model will break down with a country risk of natural disasters and decline in the labor force population.  The revival of the global competitiveness and synthetic business will depend on the success of continuous manufacturing, “production of the required quantity at the required timing using the minimum production facilities”.


19 April, 2018
F-6
10:20
|
11:40
【F:6 Organizer - Ministry of Health, Labour and Welfare
Medical Venture Supports by Ministry of Health, Labor and Welfare
Mr. Yoshinori Ikeura,
Chief Executive Officer & Chief Science Officer,
Axcelead Drug Discovery Partners, Inc

Mr. Hardy T S Kagimoto,
President, Representative Director and CEO HEALIOS K.K.

Mr. Akihiko Soyama,
President and CEO, Director
Life Science Innovation Network Japan, Inc

Mr. Yuji Tokumasu,
Professor, Osaka University Graduate School of Medicine
Head, Office for Medical/Healthcare Start-Up Support & Promotion sub-Director,
Strategic Global Partnership & Cross-Innovation Initiative, 
Osaka University Graduate School of Medicine/Osaka University Hospital

Mr. Yasuo Iimura,
Director, Health Policy Bureau, Economic Affairs Division, Venture Support Office,
MHLW(Medical venture support by Ministry of Health, Labour and Welfare)

Mr. Shuji Honjo,
Managing Director, Honjo International
Chair of the Council for Fostering Medical Ventures
The Ministry of Health, Labor and Welfare provides supports for medical ventures based on the report of the Advisory Panel for Promotion of Medical Ventures released in July 2016. We established Venture Support Strategy Office within the Ministry in April 2017. In this session, introduce the outline of the support measures for medical ventures.
Mr. Yoshinori Ikeura
Mr. Hardy T S Kagimoto
Mr. Akihiko Soyama
Mr. Yuji Tokumasu
Mr. Yasuo Iimura
Mr. Shuji Honjo


F-7
12:00
|
12:45
Made-in-Japan platform technology for therapeutic antibody manufacturing
–Perspective for Project MAB
Dr. Takeshi Omasa,
Project Leader, Manufacturing Technology Association of Biologics
Profesor, Graduate School of Engineering, Osaka University
Visiting Professor, Tokushima University
Visiting Professor, Kobe University

Five year AMED project for made-in-Japan platform technologies for therapeutic antibody production finished at this March: I would like to conclude the achievements of this projects and perspective for paradigm shift in Japan.
 


F-8
13:15
|
14:40
Next generation manufacturing of Biologics: Impact and Perspective
Dr. Takeshi Omasa,
Project Leader,
Manufacturing Technology Association of Biologics
Profesor, Graduate School of Engineering, Osaka University
Visiting Professor, Tokushima University
Visiting Professor, Kobe University

Dr. Masamichi Kamihira,
Sub-project leader,
Manufacturing Technology Association of Biologics
Professor, Department of Chemical Engineering,
Kyushu University

Dr. Sei Murakami,
Sub-project leader,
Manufacturing Technology Association of Biologics
COO, Industry & Distribution Business Unit,
Hitachi, Ltd.

Dr. Shuichi Yamamoto,
Sub-project leader,
Manufacturing Technology Association of Biologics
Professor, Graduate School of Medicine,
Yamaguchi University

Dr. Shinya Honda,
Sub-project leader,
Manufacturing Technology Association of Biologics
Deputy Director, Biomedical Research Institute,
National Institute of Advanced Industrial Science and Technology (AIST)

Dr. Kazuhisa Uchida,
Sub-project leader,
Manufacturing Technology Association of Biologics
Professor, Graduate School of Science, Technology and Innovation,
Kobe University
From FY2013-2017, the Manufacturing Technology Association of Biologics (MAB) developed integrated technology platforms for the therapeutic antibody production. In this presentation, five teams will summarize the results and discuss the next-generation technologies and platform for therapeutic antibody production. 
Dr. Takeshi Omasa
Dr. Masamichi Kamihira
Dr. Sei Murakami
Dr. Shuichi Yamamoto
Dr. Shinya Honda
Dr. Kazuhisa Uchida
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


F-9
15:00
|
16:00
Domestic active pharmaceutical ingredients market
Mr. Hikosaburo  Ubunuki,
Executive  expert, Life Science Industry,
Yano Research Institute Ltd.

I review the movement of active pharmaceutical ingredients market, and introduce current trends in Japanese market. Domestic pharmaceutical industry companies tend to change for outsourcing services, and contract manufacturing market is going continue to grow. I would like to think about change in the market environment and future prospects.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


20 April, 2018
F-10
10:30
|
11:30
Self-imposed Standards of GMP for Pharmaceutical Excipients (2016)
1. Self-imposed Standards of GMP for Pharmaceutical Excipients (2016)
Dr. Kentaro Hara,
Principal Inspector,
Office of Manufacturing/Quality and Compliance,
Pharmaceuticals and Medical Devices Agency

2. Supplier Controls of Pharmaseutical Excipient Products
Dr. Keiji Kijima,
Exective Director, 
General Incorporated Association
International pharmaceutical Excipients Council Japan
 
We updated “Self-imposed Standards of GMP for Pharmaceutical Excipients” as the regulatory research activity supported by Ministry of Health, Labor and Welfare Grants.  Here we show the history of GMP for Pharmaceutical Excipients, and explain the point of view of the updated GMP standards for Pharmaceutical Excipients.
Dr. Kentaro Hara
Dr. Keiji Kijima


F-11
12:00
|
13:00
Current status and issues of regenerative medical industry in Japan
Mr. Keita Maeda,
Deputy Director, Bio-Industry Division,
Commerce and Service Industry Policy Group Ministry of Economy, Trade and Industry, Government of Japan

Regenerative medicine market is expected to be a future growth field and driver of economic growth. The Japanese government improves optimum conditions for regenerative medicine by introducing programs, such as establishment of new legal framework and setting up of national strategic economic zones. This session aim to introduce Japanese policy to become a global collaboration hub, where RM products will be commercialized earliest in the world.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


F-12
13:20
|
14:20
Japan’s Position in a Global Regenerative Medicine Market
Mr. Colin Lee Novick,
Managing Director,
CJ PARTNERS Inc.

As the document is still being created at the time of this message, the exact nature of the presentation is still not finalized.  However, the current plan is to look at the current status of cellular and gene therapy development across the globe, and provide an overview of Japan’s position within an evolving regenerative medicine market.  The data that will be drawn on will most likely include “approved therapies,” “clinical stage therapies & those earlier,” and a “comparative analysis of regulations across multiple jurisdicitons.”


F-13
14:40
|
15:40
Regeneration and Modeling of CNS disorders using Stem Cell Technologies
Prof. Hideyuki Okano,
Dean, Keio University Graduate School of Medicine,
Professor, Department of Physiology,
Keio University School of Medicine
 

Ten years have passed since iPS cells (iPSCs) technology was developed. Currently, we are aiming to start First Human Trial of iPSCs-based cell therapy to patients with spinal cord injury using clinical grade human iPSCs stock to be delivered from CiRA. On the other hand, disease modeling is another application of iPSCs technology.  Up to now, we have established iPSC lines from over 40 psychiatric and neurological diseases patients. We would like to outline the results of pathophysiology and drug discovery research explaining the case for ALS.


F-14
16:00
|
16:55
Three Elements Important for Industrialization of Regenerative Medicine
Mr. Seiichi Kiso,
President & Chief Executive Officer,
Life Science Institute, Inc.

I believe it is important to satisfy three elements of value, accessibility and sustainability in order to realize industrialization of regenerative medicine.

In other words, it is vital to provide high clinical value that fulfills unmet medical needs, treatment that many patients can access, and in order to ensure the sustainability of such healthcare the business established must be prosperous.
 
Based on the said viewpoint, I would like to talk about industrialization of regenerative medicine including Muse cells that we are developing.


Drug Delivery System & Drug Packaging Technology

Venue: Seminar Room D, East Hall 1
Capacity: 100 Seats
18 April, 2018
D-4
15:00
|
16:00
Considerations for Selecting Drug Delivery Systems
Dr. Theresa Bankston,
Director, Technical Services, BD Medical – Pharmaceutical Systems,
Becton Dickinson Co. Ltd.,

【Language: English/Japanese】

The requirements for biologic drug approval continue to grow, with an overall aim to improve patient safety, experience and health outcomes while managing cost. With increased competition, defining drug development strategies which properly consider the delivery system is critical to a program’s success.
This session will cover technical considerations and testing strategies to optimize the selection of delivery systems and prove their suitability, compatibility, and performance with the drug as a combination product.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


19 April, 2018
D-5
11:00
|
11:30
Application of Human Factor to West’s electronic wearable drug delivery systems for large volume, high viscosity biologics
Dr. Randy Y. Adachi,
Director, Technical Operations,
Innovation & Technology, Marketing,
West Pharmaceutical Services, Inc.



D-6
11:45
|
12:15
Analysis of Extractables/Leachables and global regulation/guideline
Mr. Masaaki Suzuki,
Agilent Technologies Japan, Ltd.

Agilent presents “Analysis of Extractables and Leachables.”  We’ll make a comprehensive review of current analytical methodologies and the regulatory landscape, as well as showing best practices for designing and setting up a study.


D-7
13:00
|
13:30
Mr. Tetsuya Suzuki
Innovative Technology for Glass Primary Containers
~DLC Surface Coating Technology~
Mr. Tetsuya Suzuki,
Professor, Department of Mechanical Engeneering, Faculty of Science and Technology
Professor, Center for Science of Environment and Energy
Director of Keio Leading-edge Laboratory of Science and Technology
Keio University

Mr. Hiromasa Ookawa,
Syringe Project Manager, PharmaPackaging Division,
NIPRO CORPORATION



D-8
13:45
|
14:15
VIALEX® Premium Technology for Surface Control
Mr. Minoru Takeuchi,
General Manager, PharmaPackaging Division,
NIPRO CORPORATION



D-9
14:30
|
15:30
Usability of Glass versus Polymer Ampoules:  A comparison
Dr. Michael W. Spallek,
Head, R&D,
Rommelag
The present work compares the performance of glass and polymer ampoules especially with respect to end-user handling (usability). Glass ampoules need needles for the transfer into syringes; whereas polymer ampoules can be connected directly to Luer or LuerLock syringes. During the development of polymer ampoules produced by blow-fill-seal technology challenges arose from collapsibility and fit to many different syringes designs worldwide. Results will be presented and discussed in detail.


BioPharma Seminar

BioPharma Seminar

Venue: Seminar Room L, East Hall 1
Capacity: 100 Seats
18 April, 2018
L-1
10:30
|
11:15
【Special Seminar
The paradigm shift to realize the improvement of production efficiency and cost reduction in biopharmaceutical manufacturing.
Mr. Motoyoshi Okamura,
President,
Pharmatelier Inc.

The molecule target antibody and the immune check point inhibition antibody are showing remarkable cancer therapeutic effect whereas it is difficult to treat a cancer with one kind of antibodies and the necessity to treat using more than one antibody is rising. This means coming the time which should make paradigm shift from one kind of mass production to the multi-production in smaller scale.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


L-2
11:30
|
12:15
The ABC of Monoclonal Antibody Characterization: from the conventional analytical method to the latest one
Kentaro Takahara Ph.D,
Senior Specialist,
Chromatography & Mass Spectrometry Div. Marketing,
​Thermo Fisher Scientific K.K.

Biopharmaceuticals are large complex molecules, resulting that various assays have been used for their characterization.
This seminar will summarize the conventional LC methods for monoclonal antibody characterization, show the results of antibody using the latest technology such as capillary electrophoresis/MS and LCMS, and finally propose how to use the conventional LC method and the latest methods appropriately.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


L-4
14:00
|
14:45
The SMART Factory: end-to-end, modular automation for multiple processing platforms
Ms. Fionn Huang,
Enterprise Sales Manager, APAC,
Finesse, a part of Thermofisher Scientific,
Thermo Fisher Scientific Inc.

【Language: English/Japanese】

As the challenges in biologics and vaccine manufacturing increase with fewer blockbuster drugs, emerging markets, patent expiration, shorter time-to-market, price pressures, and increased regulatory complexity, companies are turning to multi-product single-use facilities that can provide higher yield production with fewer employees and lesser capital cost.
SmartFactory is an operations management solution for single-use facilities that optimizes plant-wide resource utilization, integrates manufacturing (batch) information, and facilitates training and validation record management. SmartFactory has been optimized to increase productivity and maximize asset utilization, while retaining an open architecture. Bio-production process flows can be designed in a modular and scalable manner, using best-of-breed equipment (including Finesse SmartSystems), without compromising quality or compliance.


L-5
15:00
|
15:45
Advanced QA/QC characterization
 MS in QC : Multi Attribute Method
Ms. Kaori TAGUCHI,
Senior Specialist, Chromatography & Mass Spectrometry Div. Business Development,
Thermo Fisher Scientific K.K.
 

The reliable and efficient Multi Attribute Methods (MAM) using a high resolution mass spectrometer (HRMS) has received attentions recently in order to monitor critical quality attributes (CQA) of biopharmaceuticals.
It is crucial for QC to comply with GxP regulatory requirements when HRMS is utilized under QC environment. In this seminar we will introduce regulated MAM workflow and solutions that enable it.


L-6
16:00
|
16:45
【Special Seminar
Current trends and perspectives in development of innovative therapeutic antibodies
Dr. Akiko Ishii-Watabe,
Director, Division of Biological Chemistry and Biologicals,
National Institute of Health Sciences

Therapeutic monoclonal antibodies have been developed as innovative drugs in each era. Several products are listed in the SAKIGAKE, and development of other novel innovative products is expected. In this presentation, current trends in development of therapeutic antibodies will be reviewed, and then consideration in safety assurance of clinical studies as well as product quality control will be discussed.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


20 April, 2018
L-14
10:30
|
11:15
【Special Seminar
Aptamers as therapeutic middle molecules
Dr. Yoshikazu Nakamura,
President and Chief Executive Officer,
RIBOMIC Inc.
Professor Emeritus,
The University of Tokyo

Therapeutic molecules can be classified as low, middle and high-molecular weight drugs depending on their molecular masses. Aptamers are middle-molecular weight molecules that are short, single-stranded nucleic acid sequences that are selected in vitro from large oligonucleotide libraries based on their high affinity to a target molecule. Recently, therapeutic middle molecules gain considerable attention as protein-protein interaction (PPI) inhibitors. This lecture summarizes our recent achievements in aptamer development in terms of PPI and non-PPI inhibitors, some of which proceed to clinical trials.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


L-15
11:30
|
12:15
Introduction of monoclonal antibody analysis and simple charge variant analysis using pH gradient buffer
Ms. Yasuko Honjo,
Application Specialist,
Chromatography & Mass Spectrometry Div.,
Thermo Fisher Scientific K.K.

Recently many monoclonal antibody drugs are under development, and researchers need to characterize those drug candidates. Following topics are presented in this session.
  • Introduction of protein analysis using various columns
  • Mechanisms of pH gradient buffer
  • Introduction of simple and rugged charge variant analysis using pH gradient buffer
  • Fast method development using pH gradient buffer


L-16
13:00
|
13:45
How to comply with Data Integrity : Introduction of Informatics solution
Mr. Tadayuki Tachibana,
Manager, Chromatography & Mass Spectrometry Div.,
Thermo Fisher Scientific K.K.
 

Overview of Data Integrity and introduction of Informatics Solution for compliance with Data Integrity


L-18
15:00
|
15:45
The latest trend and some case studies on the development of the downstream processes for the biotherapeutic drugs
Mr. Hiroaki Hamana,
Product Manager, Process Chromatography Unit,
Bio-Rad Laboratories

Mr. Koji Nakamura,
Product Manager, Process Chromatography Unit,
Bio-Rad Laboratories

 
What you develop the robust purification processes by combining some chromatography media effectively has been one of the key factors to achieve the projects in success at the manufacturing scale for the biotherapeutic drugs.
In this presentation, we would like to introduce you some case studies and our Bio-Rad’s process chromatography solutions.
Mr. Hiroaki Hamana
Mr. Koji Nakamura


L-19
16:00
|
16:45
【Special Seminar
Frontiers of human organoid research aiming for application to innovative drug discovery
Dr. Hideki Taniguchi,
Professor, Department of Regenerative Medicine,
Yokohama City University, Graduate School of Medicine

The tumor stroma microenvironment as mediator of cancer drug resistance are frequently discovered in various types of cancer. To evaluate relations between tumor stroma and pancreatic cancer drug resistance, we developed a special stroma-rich pancreatic cancer organoid (PCO) system, with recapitulation of multilineage interactions among patient-derived pancreatic cancer, endothelial and mesenchymal cell. Here, we will introduce the latest research findings on drug development based on this PCO system.


Bio CMO Seminar

Venue: Seminar Room L, East Hall 1
Capacity: 100 Seats
19 April, 2018
L-10
13:45
|
14:15
A unique protein expression service Corynex® and cGMP manufacturing
Mr. Yasuhiro Takenaka,
Manager, Pharmaceutical Custom Manufacturing Dept.,
​Ajinomoto Co., Inc.

An innovative protein/peptide expression system Corynex® using gram-positive microbial fermentation provides significant advantages over other expression systems.  High purity and productivity with secretion into culture medium with correct folding enables simplified and cost competitive production of biologics, which has been used for clients’ projects in Japan, US, and Europe. Case studies of recent cGMP production at Ajinomoto Althea Inc. will also be introduced on this seminar.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


L-11
14:30
|
15:00
Introduction of CDMO service for oligonucleotides and peptides ~ from development examples by AJIPHASE® and SPPS
Mr. Toru Okamatsu,
Manager, Business Development Division,
GeneDesign, Inc.

Recently, oligonucleotides and peptides is increasingly attractive more and more as drug candidates. CDMOs (Contract Development Manufacturing Organization) play a very important role for developing these compounds because many know-hows and special technologies are needed to manufacture such compounds. We introduce AJINOMOTO group’s CDMO service for oligonucleotides and peptides in this seminar by using recent development examples.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


L-12
15:15
|
15:45
CDMO Business for Bio-pharmaceutical in Kishi Kasei Co., Ltd.
Dr. Katsumi Nakamura,
CMC Director, Pharmaceutical Division,
Kishi Kasei Co., Ltd.

CDMO Business for Bio-pharmaceuticals in Kishi Kasei is introduced. The stages from drug discovery to commercial manufacturing are covered by using single-use system under GMP. The strategy of manufacturing technology and advanced analytical system could be shown.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


L-13
16:00
|
16:45
【Special Seminar
Strategic Analysis and Investment Decision Making on Bio CMO
Dr. Makoto Kuroki,
Associate Professor, Faculty of Economics and Business Administration,
Yokohama City University

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


BioPh Japan 2018 Panel discussion

Venue: Room 605, Conference Tower 6F
Capacity: 200 Seats
20 April, 2018
L-20
14:00
|
15:30
Directionality of Contract Manufacturing Organization (CMO) development and Issues to strengthen international competitiveness of the biopharmaceutical industry in Japan.
【Moderator】
Mr. Hiroyuki Sakamaki  
Professor 
Tokyo University of Science, School of Management, Department of Management
 
【Panelists】
 
Mr. Masanobu Yamate
Deputy Director, Economic Affairs Division, Health Policy Bureau, Ministry of Health, Labour and Welfare
 
Mr. Junichi Koga
Ph.D. Senior Executive Officer, Head of R&D Division,
Daiichi Sankyo Co., Ltd.
 
Mr. Kimio Esumi
Managing Director, Biologics Center for Research and Training
 
Mr. Rin Sano
Director, Business and Planning Officer
General Manager, Customer Project Department
A lack of investment by Japanese companies in biopharma development in the 1990’s has resulted in them now lagging behind in international competitiveness. Overseas companies, such as those from Korea and Singapore, are currently leading the filed in terms of CMO.
Panelists in this session will discuss what needs to be done to correct this situation in terms of government support, the current needs and future expectations on CMO by Japanese pharmaceutical companies, the development of the necessary human resources, and Japan's management strategy for CMO.
Mr. Hiroyuki Sakamaki
Mr. Junichi Koga
Mr. Kimio Esumi
Mr. Rin Sano


InnoPack Japan Conference

The latest tread for Pharmaceutical Packaging Technology

Venue: Seminar Room J, East Hall 1
Capacity: 100 Seats
18 April, 2018
J-1
10:30
|
11:30
1. Introduction 

2. Paradigm shift of ICT technology in pharmaceuticals
(Counterfeit drug countermeasures, fraudulent distribution countermeasures)
1. Dr. Teruko Imai, Professor, Grduate school of Phrmaceutica Scinces, Kumamoto University 

2. Mr. Yoshitaka Shimada,
Managing Director,
SIGMA P.I.CO.,LTD.
TOKYO IYAKUSHIKI

Counterfeit medicines countermeasures, illegal distribution measures.Today, things using ICT are also rapidly introduced a lot.Following last year, the characteristics of various countries and the characteristics of various countries got from the field of counterfeiting prevention inside and outside.We report the latest situation of "PharmaGrid®" and "scryptoTRACE®" using smartphone.


J-2
13:00
|
13:50
Coming soon!
Mr. Koji Nonomura,
Takeda Pharmaceutical Company Limited. 

The popularization of carbon neutral biomass (plant-derived) plastics is advancing in the food and consumer goods industry due to advances in biochemistry technology, but the pharmaceutical industry has not done at all. Takeda has begun to adopt bio-polyethylene bottles for pharmaceutical use which is made from plastic derived from sugarcane-based bioethanol. In this seminar, I would like to anticipate the movement of the pharmaceutical industry in the future along with the introduction of the contents for adoption.


J-3
14:20
|
15:10
Development and verification of CRP that is added at dispensing site to prevent children from accidental ingestion of drugs.
Mr. ATOJI Ryuta,
Section Chief, Packaging Design and Development Section
Medical Information Section,
Toyama Sugaki Co., Ltd.

Since caution was issued regarding children accidental ingestion of drugs, both pharmaceutical companies and packaging suppliers have taken several measures. However, due to circumstances peculiar to Japan including dispensing methods, care for the elderly, and cost, no significant progress has been seen. Based on the development of CRP that can be supplied only to people who need and verification of its effectiveness, I would like to consider what we can do now.


J-4
15:40
|
16:30
Quantitative Descriptive Analysis (QDA) and Temporal Dominance of Sensation (TDS) in Sensory Evaluation
Dr. Shigeru Ichihara,
Director, Institute for Sensory Evaluation,
MEDIA EYE Corporation

Quantitative Descriptive Analysis (QDA) and Temporal Dominance of Sensation (TDS) are gathering attention in sensory evaluation. In this lecture, the methods will be expounded, and the application of the methods to packaging will be discussed.


The latest information on Drug Delivery System

Venue: Seminar Room J, East Hall 1
Capacity: 100 Seats
19 April, 2018
J-5
11:00
|
11:50
Drug Delivery System for Cancer Therapy
Dr. Nobuhiro Nishiyama,
Professor, Institute of Innovative Research
Tokyo Institute of Technology

DDS is a promising technology for improving the efficacy and safety of anticancer agents including nucleic acids by the control of their biodistribution. In this lecture, I would like to introduce the principle of designing DDS and recent achievements in the related fields.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


J-6
13:00
|
13:50
The Latest Trend of DDS Technology in the Field of Regenerative Medicine
Drs. Yasuhiko Tabata,
Professor, Laboratory of Biomaterials, Department of Regeneration Science and Engineering,
Institute for Frontier Life and Medical Sciences, Kyoto University
 

For regenerative medicine defined as medicine based on the natural-healing potential of body itself, it is of prime importance to enhance the cell ability for proliferation and differentiation which governs the natural-healing potential. DDS to deliver drugs to act on cells is an indispensable technology and methodology to enhance the cell ability. This paper introduces the latest trend of DDS technology in the field of regenerative medicine.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


J-7
14:20
|
15:10
Development of Intranasal Inactivated Influenza Vaccine
Dr. Hideki Hasegawa,
Director, Pathology,
National Institute of Infectious Diseases

Intranasal administration of a vaccine induces cross-protective secretory IgA (S-IgA) antibodies on the surface of nasal mucosa which is not induced by parenteral injection of the vaccine. S-IgA antibody in nasal mucus can, unlike serum IgG, prevent homologous and heterologous virus infection.


J-8
15:40
|
16:30
Drug Delivery System necessary to pediatric medication
Mr. YOICHI ISHIKAWA,
professor, Department of Pharmacy,
Meiji Pharmaceutical University
National Center for Child Health and Development

Actually, the way to get a child to take medicine is more important than a side effect information for the family. The bitter oral medicine and the painful injection are disadvantageous to a child. When we can develop the medicine a child likes, it'll be the same effect as new medicine development. Today, we'd like to discuss DDS a child desires.


Recommendation from the frontline of medical care

Venue: Seminar Room J, East Hall 1
Capacity: 100 Seats
20 April, 2018
J-9
10:30
|
11:20
Relationship between radiological medical field and pharmaceutical packaging
Dr. Morio Shimada,
Professor, Faculty of Health Sciences,
Komazawa University

We introduce the basic study contents of tomosynthesis which is a radiation detection method with high detection power and little exposure in various candidate materials having X-ray blocking performance in case of aspirating PTP sheet.
We describe the outline of the change of the diagnostic modality (high-speed annotation of the contrast agent) and the advance of the prefilled chemical container and packaging accompanying the development of the CT diagnostic device.


J-10
13:00
|
13:50
Considering in-house medical care from the standpoint of progress of insulin injection equipment and its safety
Dr. Fumiatsu Yakushiji,
Director, Internal Medicine,
Tokyo Metropolitan Bokutoh Hospital

Currently many medical practices are being conducted in the name of in-house medical care. Due to the increasing number of elderly diabetes patients, insulin injection is being performed by a trained family or a visiting nurse. Needlestick injuries which occur in hospital also happen at home by caregivers. Since insulin injection is a common homecare, this speech is to consider the in-house care from a standpoint of insulin injection problem.


J-11
14:20
|
15:10
Recommendations for medicine packaging from the home care Field Ⅱ
Mr. Shinya Aoki,
(Nurse.  Public Health Nurse.  Care Manager)
CEO, NCCS Co., Ltd.
 

There are cases in which senior citizen, home caregiver, etc., administer and control medicine for the senior citizen who is the main of the subjects of home healthcare. For the above background, packaging and display of medicine that i9 easy to handle for senior citizen and non-health professions are required. Under these circumstances, I report on the present situation and issues from the point of view that nursing at home healthcare.
The center of the subjects of home medical care is the elderly, most of them receiving medication. And, there are cases in which the elderly, home helper, etc. manage drugs and medicines for the drugs. Against this background, packaging and display of drugs that are easy to handle and easy to handle are required for elderly people and non-medical care professionals. Under these circumstances, report on the present situation and issues from the standpoint of practicing home care.


Process Chemistry Seminar

The role of Process Chemistry for medical products - The introduction of the case studies and the latest trends

Venue: Seminar Room D, East Hall 1
Capacity: 100 Seats
20 April, 2018
D-10
10:30
|
11:30
The Mission and Future Vision of JSPC and Development of Process Chemistry-conscious Reactions based on the Heterogeneous Catalysts and Hydrogen
Dr. Hironao Sajiki,
President,
The Japanese Society for Process Chemistry
Professor, Laboratory of Organic Chemistry,
Gifu Pharmaceutical University

First of all, I will present a brief discussion of the mission and future vision of the Japanese Society for Process Chemistry (JSPC). Subsequently, several environmentally and process chemistry friendly novel reactions via C-H activation process based on the activation of a heterogeneous metallic catalyst by hydrogen such as dehydrogenative oxidation of alcohols and saturated cyclic hydrocarbons, reduction of aromatic nuclei, H-D exchange reaction and so on, will be outlined.


D-11
11:30
|
12:15
Mr. Shimizu,
Chugai Pharmaceutical Co., Ltd. 

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


D-12
13:00
|
13:45
The Mission of Process Chemistry for Pharmaceutical Development
Dr. Shigeru Ieda,
 Vice President, Process Chemistry Labs. Pharmaceutical Technology,
Astellas Pharma Inc.

In this seminar, the mission of process chemistry for pharmaceutical development would be explain with some examples and studies in Astellas Pharma Inc.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


D-13
14:00
|
14:45
Innovative Technologies for Pharmaceutical Process Development
Dr. Masaru Mitsuda,
General Manager,
Biotechnology Research Laboratories,
Kaneka Corporation

In modern pharmaceutical process researches, it is required to establish a system for speedy construction of a production method, which is not only economic but also safe and robust under strict GMP control. In order to meet these demands, we are ready to provide solutions for a variety of issues about API production utilizing novel asymmetric synthesis and the flow reaction system developed as our core technologies. 
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


D-14
15:00
|
15:45
Pharmaceutical process development oriented toward commercial production
Dr. Kazuhiko Takahashi,
Executive Director,
Technology Research & Development Division,
Sumitomo Dainippon Pharma Co., Ltd. 

The development of an efficient manufacturing process oriented toward commercial production of antihypertensive, DSP-9599 featuring strong renin inhibitory activity will be presented. Due to the multi-step route at the initial route, the use of expensive raw materials, and low yield, it was necessary to make a major improvement in terms of manufacturing cost. We found a new synthesis route by short-term investigation and established an efficient production method by telescoping.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


Japan Analytical Instruments Manufacturers' Association (JAIMA) Semminar

Venue: Room (2), East Hall 1 (on the 2nd floor)
Capacity: 40 Seats
18 April, 2018
M-1-2
10:30
|
11:20
New Application and Encountering Subjects for Instrumental Analytical
Mr. Kyoichi Komori,
Japan Analytical Instruments Manufacturers' Association

Latest analysis study of crystal polymorphism in pharmaceutical compounds
-SEM · solid state NMR · Raman · TG-MS-


Mr. Yoshiyuki Itoh,
Application Management Department Medicine Team,
​JEOL Ltd.

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-3
11:40
|
12:20
Validity Study for Combination of Volumetric and Coulometric Methods
in Karl Fischer Water Titration
Ms. Ikumi Kurose,
Technological Development Div. First Development Dept. First Product Development Sect.,
Kyoto Electronics Manufacturing Co., LTD.

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-4
13:20
|
14:00
From Three Years to Three Days: Stability Testing
with the Agilent HPLC and iChemExplorer
Mr. Akio Kori,
Pharmaceutical Business Development Manager & LC marketing,
Agilent Technologies

 

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-6
14:20
|
15:00
Component and Contaminant Analysis of Pharmaceuticals using EDX and FTIR
Ms. Fuji Risa,
Global Application Development Center Analytical & Measuring Instruments Division,
​Shimadzu Corporation

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


Academic Seminar (BioPh)

Venue: Room (2), East Hall 1 (on the 2nd floor)
Capacity: 40 Seats
20 April, 2018
M-13
10:30
|
11:15
Human-derived peptides that promotes membrane penetration of proteins: Application for intracellular delivery of biopharmaceuticals
Dr. Nobuhide Doi,
Professor, Department of Biosciences and Informatics,
Keio University

We identified novel membrane-penetrating peptides from human proteins which are involved in membrane fusion. The peptides were used to deliver various proteins to the cytoplasm of various human cell lines with high efficiency and no-cytotoxicity, and thus can be applicable to intracellular delivery of biopharmaceuticals.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-14
11:30
|
12:15
Cytosolic antibody delivery using spider toxin-derived peptides
Mr. FUTAKI Shiroh,
Professor, Institute for Chemical Research,
Kyoto University

There are accumulating demands to efficiently deliver antibodies and other bioactive proteins into living cells. Endocytosis plays a role in the delivery of these molecules into cells. These molecules cannot exert their bioactivities without escaping from the endosomes into the cytosol, prior to interacting with their targets. We designed peptides, derived from a spider toxin, to efficiently deliver bioactive proteins into cytosol by selectively disrupting endosomal membranes.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-15
13:00
|
13:45
Mr. Yasuyuki Ueda,
Graduate School of Medicine and Faculty of Medicine, The University of Tokyo

FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-16
14:00
|
14:45
Immobilization and physical adsorption of colloidal particles using polymer hydrogels
Dr. Junpei Yamanaka,
Professor, Graduate School of Pharmaceutical Sciences,
Nagoya City University

We report immobilization and adsorption of colloidal particles by using polymer hydrogels. In particular, we present that the hydrogel surfaces significantly adsorb colloidal particles in water, even in the absence of special adsorbent on the gels, because van der Waals attraction.


M-17
15:00
|
15:45
Development of peptide carrier for facilitating intestinal absorption of macromolecular drugs
Dr. Sumio Ohtsuki,
Professor, Department of Pharmaceutical Microbiology,
Faculty of Life Sciences, Kumamoto University

Oral administration is safe and easy route. Therefore, the development of carrier facilitating intestinal absorption of macromolecular drugs were important DDS technology, because of accelerating drug development and improving QOL of the patients. In this lecture, we will introduce the novel peptide carriers facilitating intestinal permeability, and present the latest data of its ability.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


M-18
16:00
|
16:45
Hinge-deficient IgG1 Fc fusion
Dr. Atsushi Sato,
Professor, School of Bioscience and Biotechnology,
Tokyo University of Technology

A widely used strategy for increasing the stability of therapeutic proteins in vivo is to fuse them with the IgG Fc domain. However, Fc fusions elicit problematic effector functions. To address this drawback, we have developed a hinge-deficient Fc-fusion platform.  A hinge-deficient Fc-fusion protein exhibited improved pharmacokinetics without enhancing effector functions.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


International Seminar

International Group Presentation

Venue: Seminar Room B, East Hall 3
Capacity: 60 Seats
19 April, 2018
B-12
13:45
|
14:15
Spanish Companies: among the leaders in the pharmaceutical sector
Economic and Commercial Office, Embassy of Spain

FREE

Register
A few
20 April, 2018
B-20
13:45
|
14:15
NatiVita Research & Production Complex
Ms. Viktoriya Volotko,
Medical Advisor, Nativita

【Language: English】

-  Cancer genome research
-  Personalized DNA vaccines
-  Personalized cell vaccines
FREE

Register

India Seminar

Venue: Room 605, Conference Tower 6F
Capacity: 200 Seats
18 April, 2018
T-1
13:00
|
14:30
PHARMA & HEALTHCARE VISION: JAPAN & INDIA
Mr. Yasuhiro Nakagiri, Managing Director,
Astellas Pharma (India)

Dr. Lekh Juneja, Executive Vice President and global head of international business/R&D & Chief Health Officer (CHO) ,
Rohto Pharmaceutical Co., Ltd.
and President, MG Pharma

Mr Koji Suzuki, Managing Director,
Rohto Pharma (India) P Ltd

Dr. Puran Lal Sahu, Principal Scientific Officer,
INDIA PHARMACOPEIA COMMISSION

Dr Gurpreet Sandhu, Managing Director,
REVA PHARMA
【Language: English/Japanese】

The objective of the session is for the JAPANESE COMPANIES to share their TRUE PERSPECTIVE related to business working post their investments in India. It will be a unique FORUM with lecture & participation by senior management of the Japan Innovator & Generic Companies operating in India. It will be a forum where market dynamics of working in India will be shared across with the audience besides question & answers session. The session will bond the strength and scope of India as a DOMESTIC BUSINESS MARKET and a MANUFACTURING BASE for Japan companies to produce, carry out research & development for both REGULATED & EMERGING MARKETS.
Mr. Yasuhiro Nakagiri
Dr. Lekh Juneja
Mr. Koji Suzuki
Dr. Puran Lal Sahu
Dr. Gurpreet Sandhu


Taiwan Seminar

Venue: Room 102, Conference Tower 1F
Capacity: 100 Seats
18 April, 2018
N-1
14:30
|
16:00
Business collaboration and investment opportunity in biotechnology and pharmaceutical industry between Japan and Taiwan
Ms. Ming-Ying Yu,
Associate Technical Specialist,
Consumer Goods & Chemical Industries Division,
Industrial Development Bureau , MOEA, Taiwan

【Language: English/Japanese】
Introduce Taiwan pharmaceutical alliance website 

Mr. Yukihiko Okamoto,
Sr. Project Manager,
Department of Industrial Services,
Medical and Pharmaceutical Industry Technology and Development Center, Taiwan

【Language: English/Japanese】


Korean Pharmaceutical’s patent right

Venue: Seminar Room D, East Hall 1
Capacity: 100 Seats
18 April, 2018
D-3
13:30
|
14:30
Can the extended patent right cover the new salt form of the original drug substance
Dr.  Jong Hyeok Park,
Representative Patent Attorney,
J.H.Park & Co.

【Language: Japanese】

Korean Patent Act Article 95 provides that the effects of an extended patent right shall not extend to any other acts except the working of the patented invention with respect to such products for which approval was the basis for registering the extension. In the first ruling, Korean patent court held that the scope of an extended patent right based on a specific salt of API shall NOT cover other salts of API.


Japan Life Science Week Special Seminar

Grab the latest Women's Market! Marketing seminar for the HealthCare Industry

Venue: Room 607, Conference Tower 6F
Capacity: 200 Seats
19 April, 2018
S-1
10:00
|
11:00
How to use Woman’s Marketing’ to Increase Revenue
Strategies to take advantage of the rapidly changing mind-set of female consumers in the healthcare market
Ms. Erina Abe,
CEO
woman's

The consumer-power of women is steadily increasing in line with the growing number of working women and their longer lifespan. Attracting and keeping female customers will be an essential element of any future retail strategy. Merely presenting them with product specifications or endorsements is not enough to capture women’s spending; they need to feel in control of the purchasing decision making process. This session is filled with advice on how to use ‘Women’s Marketing’ to differentiate your products and increase sales revenue. It is a must-attend presentation for anyone involved in product planning or marketing.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


Case studies of the recent claims for pharmaceutical and medical companies

Venue: Room 607, Conference Tower 6F
Capacity: 200 Seats
19 April, 2018
S-2
11:30
|
12:30
Liability claims for pharmaceutical/medical device companies and how to mitigate risk
Ms. Kazusa Ogawa,
Dept. Manager, Life Sciences Underwriter,
Industry Practices Department,
Chubb Insurance Japan

This session will describe the risks that life science companies face when they develop and commercialize drugs or medical equipment outside of Japan.  It will provide examples of actual claims and outline internal management practices that mitigate litigation risks.


The latest trends of Cosmetics Industry

Venue: Room 607, Conference Tower 6F
Capacity: 200 Seats
19 April, 2018
S-3
13:00
|
14:00
Cosmetic Market and Innovative Technology in Japan
Mr. Junji Yamamoto,
Senior Managing Director,
JAPAN COSMETIC  INDUSTRY ASSOCIATION
With global economic growth and social advancement of women, beauty and personal care products market has been expanded. Japan is the third largest market after US and China. In the Japanese cosmetic retail market, shipment value in 2016 was approximately 1,525 billion yen (15billion USD) and increased 180 billion yen compared to the previous year, boosted by the continued sales from tourist from China and Asian and so on as well as Japan’s domestic consumption. In addition, the export value exceeded import value for the first time in 2016. The research on aging is the most important in cosmetic industry, the Japanese cosmetic industry has been putting a lot of effort into anti-aging research and the technology has made great advances.
At the IFSCC conference which is one of the largest academic meetings in the world held every two years, the research presentations from Japan always catch the world's attention due to their extremely high academic value and possibility of application. As a result, they always receive the best research award. In addition, a background of the advanced technology development has relation to Japanese traditional culture and sensitivity. The seminar introduces the Japanese sense of beauty and the backstage supporting development of high quality product.
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


S-4
14:30
|
16:00
Cosmetics Research and Development
- Fusion of technology and sensibility -
Mr. Akinobu Hayashi,
Executive Officer, Director,
Research Laboratories,
KOSE Corporation

Mr. Takashi Hasegawa,
“Kokusai shogyo” deputy editor,
KOKUSAI SHOGYO publishing corp.
Mr. Akinobu Hayashi
Mr. Takashi Hasegawa
FREE
Full
Please come to the seminar room directly. If we have available seats on the day, you can have a seat.


Digital Medicine Trend (Joint Development product of Pharmaceuticals and Medical equipment)

Venue: Room 605, Conference Tower 6F
Capacity: 200 Seats
20 April, 2018
S-5
10:30
|
11:15
Mr. Nobuyuki Kurahashi,
Vice President, Global CNS Business,
Otsuka Pharmaceutical Development & Commercialization, Inc.



Situation of Kmpo market in Japan

Venue: Room 605, Conference Tower 6F
Capacity: 200 Seats
20 April, 2018
S-6
12:30
|
13:30
Current status and issues regarding supply and quality of crude drugs for Kampo products
Mr. Minoru Nakajima,
Vice-Chairman,
Public Relations Committee,
JAPAN KAMPO MEDICINES MANUFACTURERS ASSOCIATION

Mr. Makoto Shiratori,
Chairman,
Crude Drugs Committee,
JAPAN KAMPO MEDICINES MANUFACTURERS ASSOCIATION

Mr. Kazuhiro Matsumoto,
Chairman,
Technical Committee,
JAPAN KAMPO MEDICINES MANUFACTURERS ASSOCIATION
We will introduce the activities of the Japan Kampo Medicines Manufacturers Association, and explain the current status and issues of crude drugs for Kampo products from the aspect of ensuring stable procurement and quality assurance.
Mr. Minoru Nakajima
Mr. Makoto Shiratori
Mr. Kazuhiro Matsumoto


 

English seminars or seminars with English interpretation     Full Programme
Seminar Timetable
English seminars or seminars with English interpretation
Ministry of Health, Labour and Welfare’s Special Conference
Exhibitor Showcase
  • Fine Chemicals Japan Seminar
  • CPhI Japan
  • ICSE Japan
  • P-MEC Japan
  • BioPh Japan
  • InnoPack Japan